Now, if only Mr. Market would come to his senses. I've decided that it makes no sense to sell my ACHN holdings at this point at the $30 million market cap level so I'm going to hold on until we get clinical results from ACH-1625. Like you, I'm ascribing no value to ACH-1095 or any follow-on NS4A antagonists. On that note, the CEO is speaking at two conferences next week (http://finance.yahoo.com/news/Achillion-to-Present-At-pz-15409336.html?.v=2 ) so it will be interesting to see if we get any spin on that program. I'm more interested in hearing when ACH-1625 will enter the clinic.
Market Data 
Markets 
AI
